Ovarian cancer: niraparib similarly effective in elderly patients

  • Fabbro M & et al.
  • Gynecol Oncol
  • 9 Jan 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Niraparib maintenance therapy is similarly safe and effective in older patients (age, ≥70 years) vs their younger counterparts with recurrent ovarian cancer, regardless of BRCA status.

Why this matters

  • Current guidelines recommend same standard-of-treatment for older and younger patients.

Study design

  • Randomized, double-blind, phase 3 ENGOT-OV16/NOVA trial.
  • Patients with recurrent ovarian, fallopian tube, or peritoneal cancer, with or without a germline BRCA mutation (gBRCA and non-gBRCA cohorts), were randomly assigned 2:1 to maintenance niraparib or placebo.
  • Funding: TESARO, Inc.

Key results

  • Median follow-up in the niraparib group: 17.3 and 17.2 months in patients aged ≥70 and
  • In the gBRCA cohort, niraparib prolonged median PFS vs placebo in
    • patients aged
    • patients aged ≥70 years (not reached vs 3.7 months; HR, 0.09; 95% CI, 0.01-0.73).
  • In the non-gBRCA cohort, median PFS was significantly higher with niraparib in patients aged
  • Patients aged ≥70 vs

Limitations

  • Post hoc analysis.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit